Inflammatory bowel disease: An increased risk factor for neurologic complications

World Journal of Gastroenterology

Volumn 20, Issue 5, 2014, Pages 1228-1237

  Morís, Germán ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Extraintestinal manifestations; Inflammatory bowel disease; Multiple sclerosis; Neuropathy; Stroke; Tumor necrosis factor inhibitor

Indexed keywords

CERTOLIZUMAB PEGOL; CYCLOSPORIN; NATALIZUMAB; PROTEIN C; PROTEIN S; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; BRAIN VASCULITIS; CEREBROVASCULAR DISEASE; CROHN DISEASE; DEMYELINATING DISEASE; EPILEPSY; GENE MUTATION; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOENCEPHALOPATHY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROLOGICAL COMPLICATION; NONHUMAN; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; RESTLESS LEGS SYNDROME; RISK FACTOR; THROMBOEMBOLISM; ULCERATIVE COLITIS;

EXTRAINTESTINAL MANIFESTATIONS; INFLAMMATORY BOWEL DISEASE; MULTIPLE SCLEROSIS; NEUROPATHY; STROKE; TUMOR NECROSIS FACTOR INHIBITOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; NERVOUS SYSTEM DISEASES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84893090124     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i5.1228     Document Type: Article

References (108)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-1640 [PMID: 17499605 DOI: 10.1016/s0140-6736(07)60750-8]
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713-1725 [PMID: 22047562 DOI: 10.1056/NEJMra1102942]
3. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078 [PMID: 19923578 DOI: 10.1056/ NEJMra0804647]
4. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012; 380: 1590-1605 [PMID: 22914295 DOI: 10.1016/s0140-6736(12)60026-9]
5. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012; 380: 1606-1619 [PMID: 22914296 DOI: 10.1016/s0140-6736(12)60150-0]
6. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-1122 [PMID: 11316157 DOI: 10.1111/ j.1572-0241.2001.03756.x]
7. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol 2011; 17: 2702-2707 [PMID: 21734777 DOI: 10.3748/wjg.v17.i22.2702]
8. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11: 7227-7236 [PMID: 16437620]
9. Scheid R, Teich N. Neurologic manifestations of ulcerative colitis. Eur J Neurol 2007; 14: 483-493 [PMID: 17437605 DOI: 10.1111/j.1468-1331.2007.01718.x]
10. Wills AJ, Pengiran Tengah DS, Holmes GK. The neurology of enteric disease. J Neurol Neurosurg Psychiatry 2006; 77: 805-810 [PMID: 16574728 DOI: 10.1136/jnnp.2005.085365]
11. Singh S, Kumar N, Loftus EV, Kane SV. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis 2013; 19: 864-872 [PMID: 22552994 DOI: 10.1002/ibd.23011]
12. Benavente L, Morís G. Neurologic disorders associated with inflammatory bowel disease. Eur J Neurol 2011; 18: 138-143 [PMID: 20500801 DOI: 10.1111/j.1468-1331.2010.03095.x]
13. Zois CD, Katsanos KH, Kosmidou M, Tsianos EV. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J Crohns Colitis 2010; 4: 115-124 [PMID: 21122494 DOI: 10.1016/j.crohns.2009.10.005]
14. Oliveira GR, Teles BC, Brasil EF, Souza MH, Furtado LE,de Castro-Costa CM, Rola FH, Braga LL, Gondim Fde A. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis 2008; 14: 389-395 [PMID: 17924556 DOI:10.1002/ibd.20304]
15. Elsehety A, Bertorini TE. Neurologic and neuropsychiatric complications of Crohn's disease. South Med J 1997; 90: 606-610 [PMID: 9191736]
16. de Lau LM, de Vries JM, van der Woude CJ, Kuipers EJ, Siepman DA, Sillevis Smitt PA, Hintzen RQ. Acute CNS white matter lesions in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 576-580 [PMID: 19023898 DOI: 10.1002/ibd.20792]
17. Babali A, Terzoudi A, Vadikolias K, Souftas V, Kleitsas K, Pitiakoudis M, Piperidou H, Lirantzopoulos N, Kouklakis G. Peripheral neuropathy electrophysiological screening in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2013; 25: 539-542 [PMID: 23255024 DOI: 10.1097/ MEG.0b013e32835ceca6]
18. Figueroa JJ, Loftus EV, Harmsen WS, Dyck PJ, Klein CJ. Peripheral neuropathy incidence in inflammatory bowel disease: a population-based study. Neurology 2013; 80: 1693-1697 [PMID: 23576624 DOI: 10.1212/WNL.0b013e3182904d16]
19. Gondim FA, Brannagan TH, Sander HW, Chin RL, Latov N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain 2005; 128: 867-879 [PMID: 15705608 DOI:10.1093/brain/awh429]
20. Shen TC, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D, Bosworth BP, Brannagan TH, Green PH. Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease. J Clin Neuromuscul Dis 2012; 13: 137-145 [PMID: 22538308 DOI: 10.1097/CND.0b013e31821c55a1]
21. Lossos A, River Y, Eliakim A, Steiner I. Neurologic aspects of inflammatory bowel disease. Neurology 1995; 45: 416-421 [PMID: 7898687]
22. Deepak P, Stobaugh DJ, Sherid M, Sifuentes H, Ehrenpreis ED. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther 2013; 38: 388-396 [PMID: 23802849 DOI: 10.1111/apt.12385]
23. Sassi SB, Kallel L, Ben Romdhane S, Boubaker J, Filali A, Hentati F. Peripheral neuropathy in inflammatory bowel disease patients: a prospective cohort study. Scand J Gastroenterol 2009; 44: 1268-1269 [PMID: 19681018 DOI: 10.1080/00 365520903199871]
24. de la Torre RG, Morís G, Martínez DP, Montes IC. Guillain-Barré syndrome, tuberculosis and inflammatory bowel disease: a multiple association. Int Arch Med 2010; 3: 15 [PMID:20637069 DOI: 10.1186/1755-7682-3-15]
25. Boylu E, Toǧrol E, Doǧan T, Saraçoǧlu M. Crohn disease and chronic inflammatory demyelinating polyneuropathy; a case report. Electromyogr Clin Neurophysiol 2010; 50: 181-185 [PMID: 20552951]
26. Krystallis CS, Kamberoglou DK, Cheilakos GB, Maltezou MN, Tzias VD. Guillain-Barré syndrome during a relapse of ulcerative colitis: a case report. Inflamm Bowel Dis 2010; 16: 555-556 [PMID: 19714764 DOI: 10.1002/ibd.21071]
27. Zitomersky NL, Levine AE, Atkinson BJ, Harney KM, Verhave M, Bousvaros A, Lightdale JR, Trenor CC. Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 57: 343-347 [PMID: 23752078 DOI: 10.1097/MPG.0b013e31829ce5cd]
28. Tsiolakidou G, Koutroubakis IE. Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World J Gastroenterol 2008; 14: 4440-4444 [PMID: 18680221]
29. Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 266-272 [PMID: 16265230 DOI: 10.1038/ncpgasthep0190]
30. Singh S, Singh H, Loftus EV Jr, Pardi DS. Risk of Cerebro-vascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2013 Aug 24; Epub ahead of print [PMID: 23978350 DOI: 10.1016/ j.cgh.2013.08.023]
31. Sibai M, El Moutawakil B, Chourkani N, Bourezgui M, Rafai MA, Slassi I. [Neurological manifestations of chronic inflammatory bowel disease]. Rev Neurol (Paris) 2008; 164: 859-865 [PMID: 18926245 DOI: 10.1016/j.neurol.2008.03.001]
32. Bermejo PE, Burgos A. [Neurological complications of inflammatory bowel disease]. Med Clin (Barc) 2008; 130: 666-675 [PMID: 18501131]
33. Schneiderman JH, Sharpe JA, Sutton DM. Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol 1979; 5: 331-337 [PMID: 443768 DOI: 10.1002/ ana.410050405]
34. Mayeux R, Fahn S. Strokes and ulcerative colitis. Neurology 1978; 28: 571-574 [PMID: 565888]
35. Nogami H, Iiai T, Maruyama S, Tani T, Hatakeyama K. Common carotid arterial thrombosis associated with ulcerative colitis. World J Gastroenterol 2007; 13: 1755-1757 [PMID: 17461484]
36. Zitomersky NL, Verhave M, Trenor CC. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis 2011; 17: 458-470 [PMID: 20848518 DOI: 10.1002/ibd.21334]
37. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35: 664-670 [PMID: 14976332 DOI: 10.1161/01.str.0000117571.76197.26]
38. Cognat E, Crassard I, Denier C, Vahedi K, Bousser MG. Cerebral venous thrombosis in inflammatory bowel diseases: eight cases and literature review. Int J Stroke 2011; 6: 487-492 [PMID: 22017824 DOI: 10.1111/j.1747-4949.2011.00620.x]
39. Rodríguez S, Calleja S, Morís G. Cluster-like headache heralding cerebral venous thrombosis. Cephalalgia 2008; 28: 906-907 [PMID: 18540872 DOI: 10.1111/j.1468-2982.2007.01464.x]
40. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102: 174-186 [PMID: 17100967 DOI: 10.1111/j.1572-0241.2006.00943.x]
41. Guédon C, Le Cam-Duchez V, Lalaude O, Ménard JF, Lerebours E, Borg JY. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 1448-1454 [PMID: 11374681 DOI:1235 10.1111/j.1572-0241.2001.03797.x]
42. Oussalah A, Guéant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther 2011; 34: 1173-1184 [PMID: 21967576 DOI: 10.1111/j.1365-2036.2011.04864.x]
43. Aichbichler BW, Petritsch W, Reicht GA, Wenzl HH, Eherer AJ, Hinterleitner TA, Auer-Grumbach P, Krejs GJ. Anticardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1999; 44: 852-856 [PMID: 10219848]
44. Vrij AA, Rijken J, van Wersch JW, Stockbrügger RW. Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. Pathophysiol Haemost Thromb 2003; 33: 75-83 [PMID: 14624048]
45. Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009; 104: 1445-1451 [PMID: 19491858 DOI: 10.1038/ajg.2009.81]
46. Rang EH, Brooke BN, Hermon-Taylor J. Association of ulcerative colitis with multiple sclerosis. Lancet 1982; 2: 555 [PMID: 6125706]
47. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129: 819-826 [PMID: 16143121 DOI: 10.1053/j.gastro.2005.06.022]
48. Geissler A, Andus T, Roth M, Kullmann F, Caesar I, Held P, Gross V, Feuerbach S, Schölmerich J. Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet 1995; 345: 897-898 [PMID: 7707814]
49. Dolapcioglu C, Guleryuzlu Y, Uygur-Bayramicli O, Ahishali E, Dabak R. Asymptomatic brain lesions on cranial magnetic resonance imaging in inflammatory bowel disease. Gut Liver 2013; 7: 169-174 [PMID: 23560152 DOI: 10.5009/gnl.2013.7.2.169]
50. Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IM, Sadovnick AD, Ebers GC. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007; 6: 604-610 [PMID: 17560172 DOI: 10.1016/s1474-4422(07)70132-1]
51. Sadovnick AD, Paty DW, Yannakoulias G. Concurrence of multiple sclerosis and inflammatory bowel disease. N Engl J Med 1989; 321: 762-763 [PMID: 2770807]
52. Nielsen NM, Frisch M, Rostgaard K, Wohlfahrt J, Hjalgrim H, Koch-Henriksen N, Melbye M, Westergaard T. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 2008; 14: 823-829 [PMID: 18573841 DOI: 10.1177/1352458508088936]
53. Dobson R, Giovannoni G. Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. J Neurol 2013; 260: 1272-1285 [PMID: 23315260 DOI: 10.1007/s00415-012-6790-1]
54. Menon B, Goyal R, Nihal L, Reddy R. Cerebral venous thrombosis in ulcerative colitis. J Neurosci Rural Pract 2013; 4: 84-86 [PMID: 23546367 DOI: 10.4103/0976-3147.105629]
55. Fernández-Rodríguez E, Camarero-González E. [Patient with Crohn's disease and seizures due to hypomagnesemia]. Nutr Hosp 2007; 22: 720-722 [PMID: 18051998]
56. Schluter A, Krasnianski M, Krivokuca M, Spielmann RP, Neudecker S, Hirsch W. Magnetic resonance angiography in a patient with Crohn's disease associated cerebral vasculitis. Clin Neurol Neurosurg 2004; 106: 110-113 [PMID: 15003300 DOI: 10.1016/j.clineuro.2003.09.004]
57. Pandian JD, Henderson RD, O'Sullivan JD, Rajah T. Cerebral vasculitis in ulcerative colitis. Arch Neurol 2006; 63: 780 [PMID: 16682552 DOI: 10.1001/archneur.63.5.780]
58. Ray DW, Bridger J, Hawnaur J, Waldek S, Bernstein RM, Dornan TL. Transverse myelitis as the presentation of Jo-1 antibody syndrome (myositis and fibrosing alveolitis) in long-standing ulcerative colitis. Br J Rheumatol 1993; 32: 1105-1108 [PMID: 8252324].
59. Weinstock LB, Bosworth BP, Scherl EJ, Li E, Iroku U, Munsell MA, Mullen GE, Walters AS. Crohn's disease is associated with restless legs syndrome. Inflamm Bowel Dis 2010; 16: 275-279 [PMID: 19575360 DOI: 10.1002/ibd.20992]
60. Swanson GR, Burgess HJ, Keshavarzian A. Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare? Expert Rev Clin Immunol 2011; 7: 29-36 [PMID: 21162647 DOI: 10.1586/eci.10.83]
61. Ananthakrishnan AN, Issa M, Barboi A, Jaradeh S, Zadvornova Y, Skaros S, Johnson K, Otterson MF, Binion DG. Impact of autonomic dysfunction on inflammatory bowel disease. J Clin Gastroenterol 2010; 44: 272-279 [PMID: 19727003 DOI: 10.1097/MCG.0b013e3181b2682a]
62. Boissé L, Chisholm SP, Lukewich MK, Lomax AE. Clinical and experimental evidence of sympathetic neural dysfunction during inflammatory bowel disease. Clin Exp Pharmacol Physiol 2009; 36: 1026-1033 [PMID: 19566829 DOI: 10.1111/ j.1440-1681.2009.05242.x]
63. Ohlsson B, Sundkvist G, Lindgren S. Subclinical sympathetic neuropathy appears early in the course of Crohn's disease. BMC Gastroenterol 2007; 7: 33 [PMID: 17697346 DOI:10.1186/1471-230x-7-33]
64. Summers RW, Harker L. Ulcerative colitis and sensorineural hearing loss: is there a relationship? J Clin Gastroenterol 1982; 4: 251-252 [PMID: 6124571]
65. Karmody CS, Valdez TA, Desai U, Blevins NH. Sensorineural hearing loss in patients with inflammatory bowel disease. Am J Otolaryngol 2009; 30: 166-170 [PMID: 19410121 DOI: 10.1016/j.amjoto.2008.04.009]
66. Morís G, Milla A, Ribacoba R, González C. Acute deafness as an extraintestinal manifestation of ulcerative colitis. Eur J Intern Med 2005; 16: 440-442 [PMID: 16198906 DOI: 10.1016/ j.ejim.2005.01.020]
67. Romero Aroca P, Salvat Serra M, Perena Soriano F, Martínez Salcedo I. [Anterior optic neuritis do to ulcerative colitis]. Arch Soc Esp Oftalmol 2001; 76: 189-191 [PMID: 11283786]
68. Heuer DK, Gager WE, Reeser FH. Ischemic optic neuropathy associated with Crohn's disease. J Clin Neuroophthalmol 1982; 2: 175-181 [PMID: 6217221]
69. Lloyd DA, Payton KB, Guenther L, Frydman W. Melkersson-Rosenthal syndrome and Crohn's disease: one disease or two? Report of a case and discussion of the literature. J Clin Gastroenterol 1994; 18: 213-217 [PMID: 8034917]
70. Foroozan R, Sambursky R. Ocular myasthenia gravis and inflammatory bowel disease: a case report and literature review. Br J Ophthalmol 2003; 87: 1186-1187 [PMID: 12928296]
71. McCann P, Pramanik A. Dysphagia and unexpected myasthenia gravis associated with primary biliary cirrhosis, ulcerative colitis and vitiligo. J Am Geriatr Soc 2004; 52: 1407-1408 [PMID: 15271143 DOI: 10.1111/j.1532-5415.2004.52379_7.x]
72. Finnie IA, Shields R, Sutton R, Donnelly R, Morris AI. Crohn's disease and myasthenia gravis: a possible role for thymectomy. Gut 1994; 35: 278-279 [PMID: 8307484]
73. Martin RW, Shah A. Myasthenia gravis coexistent with Crohn's disease. J Clin Gastroenterol 1991; 13: 112-113 [PMID: 2007731]
74. Gower-Rousseau C, Reumaux D, Bellard M, Delecourt L, Ribet M, Colombel JF. Remission of myasthenia gravis after proctocolectomy in a patient with ulcerative colitis. Am J Gastroenterol 1993; 88: 1136-1138 [PMID: 8317426]
75. Szabo N, Lukacs S, Kulcsar I, Gunasekera W, Nagy-Toldi A, Dezso B, Danko K. Association of idiopathic inflammatory myopathy and Crohn's disease. Clin Rheumatol 2009; 28: 99-101 [PMID: 19002546 DOI: 10.1007/s10067-008-1032-8]
76. Leibowitz G, Eliakim R, Amir G, Rachmilewitz D. Derma-tomyositis associated with Crohn's disease. J Clin Gastroenterol 1994; 18: 48-52 [PMID: 8113586]
77. Hayashi T, Nakamura T, Kurachi K, Asai Y, Nakajima A, Suzuki S, Konno H. Ulcerative colitis accompanied with sarcoidosis and dermatomyositis: report of a case. Dis Colon Rectum 2008; 51: 474-476 [PMID: 18224374 DOI: 10.1007/ s10350-007-9165-4]
78. Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013; 369: 754-762 [PMID: 23964937 DOI: 10.1056/NEJMct1209614]
79. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-1534 [PMID: 8960740]
80. Faivre A, Franques J, De Paula AM, Gutierrez M, Bret S, Aubert S, Attarian S, Pouget J. Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy. J Neurol Sci 2010; 291: 103-106 [PMID: 20116808 DOI: 10.1016/j.jns.2010.01.004]
81. Carrilho PE, Araújo AC, Alves O, Kotze PG. Motor neuropathy with multiple conduction blocks associated with TNFalpha antagonist. Arq Neuropsiquiatr 2010; 68: 452-454 [PMID: 20602052]
82. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66: 490-497 [PMID: 19364934 DOI: 10.1001/archneurol.2009.11]
83. Ramos-Casals M, Roberto-Perez-Alvarez C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010; 9: 188-193 [PMID: 19854301 DOI: 10.1016/j.autrev.2009.10.003]
84. Haddock R, Garrick V, Horrocks I, Russell RK. A case of posterior reversible encephalopathy syndrome in a child with Crohn's disease treated with Infliximab. J Crohns Colitis 2011; 5: 623-627 [PMID: 22115385 DOI: 10.1016/ j.crohns.2011.06.011]
85. Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 2014; 13: 54-58 [PMID: 24035809 DOI: 10.1016/j.autrev.2013.09.002]
86. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009; 45: 55-57 [PMID: 19109035 DOI: 10.1016/j.cyto.2008.11.002]
87. Cohen M, Baldin B, Thomas P, Lebrun C. [Neurological adverse events under anti-TNF alpha therapy]. Rev Neurol (Paris) 2012; 168: 33-39 [PMID: 22098827 DOI: 10.1016/ j.neurol.2011.06.005]
88. Cénit MC, Alcina A, Márquez A, Mendoza JL, Díaz-Rubio M, de las Heras V, Izquierdo G, Arroyo R, Fernández O, de la Concha EG, Matesanz F, Urcelay E. STAT3 locus in inflammatory bowel disease and multiple sclerosis susceptibility. Genes Immun 2010; 11: 264-268 [PMID: 20200543 DOI:10.1038/gene.2010.10]
89. Jakkula E, Leppä V, Sulonen AM, Varilo T, Kallio S, Kemppinen A, Purcell S, Koivisto K, Tienari P, Sumelahti ML, Elovaara I, Pirttilä T, Reunanen M, Aromaa A, Oturai AB, Søndergaard HB, Harbo HF, Mero IL, Gabriel SB, Mirel DB, Hauser SL, Kappos L, Polman C, De Jager PL, Hafler DA, Daly MJ, Palotie A, Saarela J, Peltonen L. Genomewide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet 2010; 86: 285-291 [PMID: 20159113 DOI: 10.1016/ j.ajhg.2010.01.017]
90. Matesanz F, González-Pérez A, Lucas M, Sanna S, Gayán J, Urcelay E, Zara I, Pitzalis M, Cavanillas ML, Arroyo R, Zoledziewska M, Marrosu M, Fernández O, Leyva L, Alcina A, Fedetz M, Moreno-Rey C, Velasco J, Real LM, Ruiz-Peña JL, Cucca F, Ruiz A, Izquierdo G. Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1. PLoS One 2012; 7: e36140 [PMID: 22570697 DOI:10.1371/journal.pone.0036140]
91. Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008; 37: 281-292 [PMID: 18041052 DOI: 10.1002/mus.20924]
92. Burger DC, Florin TH. Peripheral neuropathy with inflixmab therapy in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1772 [PMID: 19170193 DOI: 10.1002/ibd.20870]
93. Diotti RA, Nakanishi A, Clementi N, Mancini N, Criscuolo E, Solforosi L, Clementi M. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? Clin Dev Immunol 2013; 2013: 967581 [PMID: 23878587 DOI:10.1155/2013/967581]
94. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880 [PMID: 22591293 DOI: 10.1056/NEJMoa1107829]
95. Juillerat P, Wasan SK, Fowler SA, Friedman S, Pabby VK, Coukas JA, Barto AE, Pellish R, Germansky KA, Cheifetz AS, Korzenik JR, Farraye FA, Yajnik V. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis 2013; 19: 2457-2463 [PMID: 23962896 DOI: 10.1097/MIB.0b013e3182a32a0d]
96. Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M, Hanson KA, Tremaine WJ, Bruining DH, Faubion WA, Pardi DS, Harmsen WS, Zinsmeister AR, Loftus EV. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis 2012; 18: 2203-2208 [PMID: 22419661 DOI:10.1002/ibd.22943]
97. Sakuraba A, Keyashian K, Correia C, Melek J, Cohen RD, Hanauer SB, Rubin DT. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis 2013; 19: 621-626 [PMID: 23429449 DOI:10.1097/MIB.0b013e31827eea78]
98. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246: 339-346 [PMID:10399863]
99. Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005; 22: 907-916 [PMID: 16268964 DOI: 10.1111/ 1365-2036.2005.02680.x]
100. Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 937-943 [PMID: 18177449 DOI:10.1111/j.1572-0241.2007.01718.x]
101. Boyce EG, Cookson ET, Bond WS. Persistent metronidazole-induced peripheral neuropathy. DICP 1990; 24: 19-21 [PMID:2154078]
102. Schoonjans R, Mast A, Van Den Abeele G, Dewilde D,Achten E, Van Maele V, Pauwels W. Sulfasalazine-associated encephalopathy in a patient with Crohn's disease. Am J Gastroenterol 1993; 88: 1416-1420 [PMID: 8103282]
103. Olenginski TP, Harrington TM, Carlson JP. Transverse myelitis secondary to sulfasalazine. J Rheumatol 1991; 18: 304 [PMID: 1673725]
104. Alcena V, Alexopoulos GS. Ulcerative colitis in association with chronic paranoid schizophrenia: a review of steroid-induced psychiatric disorders. J Clin Gastroenterol 1985; 7: 400-404 [PMID: 2866212]
105. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001; 33: 289-294 [PMID: 11588541]
106. Mullen RS, Romans-Clarkson SE. Behavioural sensitisation and steroid-induced psychosis. Br J Psychiatry 1993; 162: 549-551 [PMID: 8481750]
107. Triantafillidis JK, Vagianos K, Rontos I. Psychotic reaction as a cardinal first clinical manifestation in a patient with Crohn's disease. J Crohns Colitis 2013; 7: e76-e77 [PMID: 22854290 DOI: 10.1016/j.crohns.2012.07.003]
108. Reimer J, Fink T, Bläker M, Schäfer I, Otte C. Successful treatment of psychosis with infliximab in a patient with Crohn's disease. Schizophr Res 2009; 109: 194-195 [PMID: 19223267 DOI: 10.1016/j.schres.2009.01.018]